BR112017007063A2 - ?composições e métodos para o tratamento de insônia? - Google Patents

?composições e métodos para o tratamento de insônia?

Info

Publication number
BR112017007063A2
BR112017007063A2 BR112017007063-4A BR112017007063A BR112017007063A2 BR 112017007063 A2 BR112017007063 A2 BR 112017007063A2 BR 112017007063 A BR112017007063 A BR 112017007063A BR 112017007063 A2 BR112017007063 A2 BR 112017007063A2
Authority
BR
Brazil
Prior art keywords
compositions
methods
treating insomnia
insomnia
dimethylpyrimidin
Prior art date
Application number
BR112017007063-4A
Other languages
English (en)
Inventor
Moline Margaret
Pastino Gina
Akimoto Yurie
Zaima Yasuhiro
Suzuki Nobuya
Yoshida Nobuo
Original Assignee
Eisai R&D Management Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co., Ltd. filed Critical Eisai R&D Management Co., Ltd.
Publication of BR112017007063A2 publication Critical patent/BR112017007063A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Anesthesiology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)

Abstract

na presente invenção, descobriu-se que compostos tais como a (1r,2s)-2-(((2,4-dimetilpirimidin-5-il)oxi)metil)-2-(3-fluorofenil)-n-(5-fluoropiridin-2-il) ciclopropanocarboxamida são potentes antagonistas de receptores de orexina e podem ser úteis no tratamento de transtornos do sono tais como insônia, assim como para outros usos terapêuticos.
BR112017007063-4A 2014-10-23 2015-10-21 ?composições e métodos para o tratamento de insônia? BR112017007063A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462067443P 2014-10-23 2014-10-23
US62/067,443 2014-10-23
PCT/JP2015/080304 WO2016063995A1 (en) 2014-10-23 2015-10-21 Compositions and methods for treating insomnia

Publications (1)

Publication Number Publication Date
BR112017007063A2 true BR112017007063A2 (pt) 2018-02-14

Family

ID=55761025

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017007063-4A BR112017007063A2 (pt) 2014-10-23 2015-10-21 ?composições e métodos para o tratamento de insônia?

Country Status (14)

Country Link
US (3) US10188652B2 (pt)
EP (1) EP3209298B1 (pt)
JP (1) JP6659681B2 (pt)
KR (1) KR102444608B1 (pt)
CN (1) CN107810006B (pt)
AU (1) AU2015336463B2 (pt)
BR (1) BR112017007063A2 (pt)
CA (1) CA2964504C (pt)
ES (1) ES2843952T3 (pt)
IL (1) IL251759B (pt)
MX (1) MX2017004950A (pt)
RU (1) RU2703297C2 (pt)
SG (2) SG10202007759RA (pt)
WO (1) WO2016063995A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015336463B2 (en) 2014-10-23 2020-06-18 Eisai R&D Management Co., Ltd. Compositions and methods for treating insomnia
KR102511855B1 (ko) 2016-05-12 2023-03-20 에자이 알앤드디 매니지먼트 가부시키가이샤 일주기 리듬 수면 장애를 치료하는 방법
IL264593B (en) 2016-08-10 2022-07-01 Hoffmann La Roche Medicinal preparations containing akt protein kinase inhibitors
CN115710250A (zh) * 2017-08-01 2023-02-24 博健制药有限责任公司 一种食欲素受体拮抗剂的晶型及其制备方法和用途
EP3883562A4 (en) 2018-11-21 2022-08-03 Tremeau Pharmaceuticals, Inc. PURIFIED FORMS OF ROFECOXIB AND METHODS OF MAKING AND USING
CN114096251A (zh) * 2019-06-26 2022-02-25 卫材R&D管理有限公司 用于治疗睡眠问题的莱博雷生
WO2020263253A1 (en) * 2019-06-26 2020-12-30 Moline Margaret Lemborexant for treating sleep issues
MX2022003018A (es) * 2019-09-13 2022-06-14 Takeda Pharmaceuticals Co Danavorexton (tak-925) para usarse en el tratamiento de la narcolepsia.
EP3993801A4 (en) * 2019-09-13 2023-07-19 Eisai R&D Management Co., Ltd. PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF INSOMNIA
BR112022012246A2 (pt) * 2019-12-20 2022-08-30 Eisai R&D Man Co Ltd Uso de lemborexant para tratar insônia
CN114901285A (zh) 2020-01-16 2022-08-12 卫材R&D管理有限公司 莱博雷生的原料药及含有其的医药组合物
BR112022020924A2 (pt) 2020-04-19 2023-02-14 Idorsia Pharmaceuticals Ltd Métodos de tratamento de um transtorno do sono, a sonolência diurna em um indivíduo, a insônia, e, daridorexante na forma de sal livre ou farmaceuticamente aceitável
CN111450076A (zh) * 2020-05-25 2020-07-28 安徽省逸欣铭医药科技有限公司 一种Lemborexant软胶囊组合物及其制备方法
WO2024064897A1 (en) 2022-09-23 2024-03-28 Eisai R&D Management Co., Ltd. Methods of reducing neurodegeneration associated with neurodegenerative diseases

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06328057A (ja) 1993-05-26 1994-11-29 Sanyo Electric Co Ltd 厨芥処理装置
EP0828751A4 (en) 1995-05-05 1999-01-20 Human Genome Sciences Inc HUMAN NEUROPEPTIDE RECEPTOR
US6309854B1 (en) 1996-12-17 2001-10-30 Smithkline Beecham Corporation Polynucleotides encoding ligands of the neuropeptide receptor HFGAN72
US6001963A (en) 1996-12-17 1999-12-14 Smithkline Beecham Corporation Ligands of the neuropeptide receptor HFGAN72
US6020157A (en) 1997-04-30 2000-02-01 Smithkline Beecham Corporation Polynucleotides encoding HFGAN72X receptor
US5935814A (en) 1997-04-30 1999-08-10 Smithkline Beecham Corporation Polynucleotides encoding HFGAN72Y receptor
US6166193A (en) 1997-07-25 2000-12-26 Board Of Regents, University Of Texas System Polynucleotides encoding MY1 receptor
AU2005250077B2 (en) 2004-03-01 2011-06-09 Idorsia Pharmaceuticals Ltd Substituted 1,2,3,4-tetrahydroisoquinoline derivatives
MX2007003377A (es) 2004-09-23 2007-05-10 Pfizer Prod Inc Agonistas del receptor de trombopoyetina.
JP2006328057A (ja) 2005-04-25 2006-12-07 Eisai R & D Management Co Ltd 抗不安薬及びそのスクリーニング方法
US20090082394A1 (en) 2006-03-15 2009-03-26 Actelion Pharmaceuticals, Ltd. Tetrahydroisoquinoline Derivatives to Enhance Memory Function
WO2007129188A1 (en) 2006-05-10 2007-11-15 Pfizer Japan Inc. Cyclopropanecarboxamide compound
CA2662538A1 (en) 2006-09-11 2008-03-20 Glaxo Group Limited Azabicyclic compounds as inhibitors of monoamines reuptake
JP2010504957A (ja) 2006-09-29 2010-02-18 アクテリオン ファーマシューティカルズ リミテッド ３−アザ−ビシクロ［３．１．０］ヘキサン誘導体
PE20081229A1 (es) * 2006-12-01 2008-08-28 Merck & Co Inc Antagonistas de receptor de orexina de diazepam sustituido
TW200833328A (en) 2006-12-28 2008-08-16 Actelion Pharmaceuticals Ltd 2-aza-bicyclo[3.1.0]hexane derivatives
NZ584050A (en) 2007-09-21 2011-09-30 Sanofi Aventis (cyclopropyl-phenyl)-phenyl-oxalamides, method for the production thereof, and use of same as a medicament
PE20091010A1 (es) 2007-10-10 2009-08-08 Actelion Pharmaceuticals Ltd Derivados de tetrahidroquinolina
US9276724B2 (en) * 2010-02-15 2016-03-01 Koninklijke Philips N.V. Mitigation of control channel interference
SI2626350T1 (sl) * 2010-09-22 2015-09-30 Eisai R&D Management Co., Ltd. Spojina ciklopropana
US20120165339A1 (en) 2010-12-22 2012-06-28 Eisai R&D Management Co., Ltd. Cyclopropane derivatives
AU2015336463B2 (en) 2014-10-23 2020-06-18 Eisai R&D Management Co., Ltd. Compositions and methods for treating insomnia

Also Published As

Publication number Publication date
US10702529B2 (en) 2020-07-07
US10188652B2 (en) 2019-01-29
MX2017004950A (es) 2018-01-16
JP2017531683A (ja) 2017-10-26
AU2015336463B2 (en) 2020-06-18
IL251759A0 (en) 2017-06-29
US20200268754A1 (en) 2020-08-27
RU2703297C2 (ru) 2019-10-16
SG10202007759RA (en) 2020-09-29
AU2015336463A1 (en) 2017-05-04
RU2017112308A (ru) 2018-11-26
IL251759B (en) 2021-01-31
US20190201399A1 (en) 2019-07-04
JP6659681B2 (ja) 2020-03-04
CA2964504A1 (en) 2016-04-28
RU2017112308A3 (pt) 2019-05-08
CN107810006A (zh) 2018-03-16
EP3209298A4 (en) 2018-06-20
WO2016063995A1 (en) 2016-04-28
SG11201703064WA (en) 2017-05-30
CA2964504C (en) 2022-08-23
US11026944B2 (en) 2021-06-08
ES2843952T3 (es) 2021-07-21
KR102444608B1 (ko) 2022-09-20
KR20170068478A (ko) 2017-06-19
EP3209298A1 (en) 2017-08-30
EP3209298B1 (en) 2020-12-02
US20170252342A1 (en) 2017-09-07
CN107810006B (zh) 2021-03-30

Similar Documents

Publication Publication Date Title
BR112017007063A2 (pt) ?composições e métodos para o tratamento de insônia?
CL2017003073A1 (es) Inhibidores de tirosina-cinasas
CL2019001344A1 (es) Composición farmacéutica para prevenir o tratar el cáncer de cerebro incluyendo el polimorfo cristalino del hexoxido tetraarsenico y el método para preparar el mismo.
CR20160485A (es) Compuesto de ciclopropanamina y sus usos
DK3889145T3 (da) 8-cyano-5-piperidino-quinoliner som TLR7/8-antagonister og anvendelser deraf til behandling af immunsygdomme
BR112017027506A2 (pt) agentes, usos e métodos para o tratamento da sinucleinopatia
MX2017005834A (es) Polinucleotidos aad para el tratamiento de la enfermedad de parkinson.
MX2018006223A (es) Moduladores de ror-gamma.
NI201600071A (es) Compuestos de inhibidor de autotaxina
MX2017005457A (es) Metodos y compuestos agonistas de gip.
SV2017005434A (es) 2-amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
PH12016502291A1 (en) Indolizine derivatives as phosphoinositide 3-kinases inhibitors
PH12017500401A1 (en) Therapeutic compounds as inhibitors of the orexin-1 receptor
PH12016500140A1 (en) Heterobicycloaryl rorc2 inhibitors and methods of use thereof
HK1252813A1 (zh) 用於治療社交障礙和藥物使用障礙的治療性化合物和組合物
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
EA201691567A1 (ru) Способы лечения легких травм головного мозга
BR112017024908A2 (pt) usos terapêuticos da 4-cloroquinurenina
GB201213484D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods of using the same
DOP2016000161A (es) Ureas asimétricas p- sustituidas y usos médicos de las mismas.
MX2017014752A (es) Nuevos etinos de amidoheteroaril aroil hidrazida.
MX2016008968A (es) Compuestos organicos.
GEP201706795B (en) Hexahydrofuropyrroles as pde1 inhibitors
PH12017501694A1 (en) Compositions for the treatment of fibrosis and fibrosis-related diseases

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.